THE CRUNCH

Isomorphic Labs, the AI drug discovery company spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz joining alongside all existing backers, including Alphabet's venture divisions. It is the lab's second mega-round within six months, following a $2.1 billion Series B in May 2026.

The company says the money will fund continued development of its drug-design engine, known as IsoDDE (Isomorphic Drug Design Engine), and push its pipeline of drug candidates towards clinical trials. The lab reports positive preclinical results in oncology and immunology, and has struck partnerships with Eli Lilly, Novartis and Johnson & Johnson, but it has no approved drug to show for its work yet.

IsoDDE builds on DeepMind's AlphaFold, the protein-structure prediction system that earned founder Demis Hassabis and John Jumper the 2024 Nobel Prize in Chemistry. According to the company, IsoDDE goes beyond AlphaFold 3 and aims to better predict how and where drugs bind to their targets.

This is Isomorphic's first fundraise since Hassabis stepped away from day-to-day leadership of Google DeepMind in August 2026 to focus on drug discovery, moving into a chairman role at DeepMind while serving as Alphabet's chief scientist. DeepMind's original AlphaFold team was disbanded in July 2026, with many researchers moving to Isomorphic Labs or other projects.

Isomorphic did not disclose its valuation. Bloomberg reported earlier this month that the lab was seeking funding at a $50 billion valuation.